anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypoxic-ischemic encephalopathy (HIE) affects approximately 1 to 2 per 1000 live births and remains a cause of significant morbidity and mortality in the neonatal period. In response to an anoxic insult, perfusion to vital organs is preserved; however, when this injury is profound concomitant injury to nonvital organs is observed. Controlled hypothermia (CH) has been accepted as a neuroprotective therapeutic modality for neonates with moderate to severe HIE because of its role in attenuating secondary brain injury. Neonates exhibit varying degrees of multiorgan dysfunction after a hypoxic-ischemic insult, although the added beneficial and potential adverse effects that CH has in these babies have not been completely delineated or understood.

CH has been shown to alter normal physiologic functioning of several organ systems. Specific physiologic changes as a consequence of CH have been demonstrated in both animal and human models. The observed reduction in cardiac output and reflexive increase in systemic vascular resistance in response to CH alter renal perfusion and subsequently reduce glomerular filtration . Drugs that are renally cleared may develop a prolonged half-life in this setting. Finally, drug metabolism may further be affected by altered hepatic blood flow and temperature-dependent effects on hepatic enzyme activity . Collectively, the potential effects of CH on drug metabolism and clearance are significant warranting further investigation. The investigator aims to evaluate the combined effects of hypoxia and hypothermia on ampicillin clearance and excretion
FIELD: preparative and technical biochemistry. SUBSTANCE: invention relates to preparing the biologically active chemical compound - protein product used both in cellular biology and practical medicine and veterinary science. Invention relates to glycoprotein isolated from animal and human blood serum of the following formula of N-terminal fragment: R-Asn-Thr-Pro-Lys-Gly-Ile-Ala-Ala-Ala-Phe-Lys where R - a residue of oligosaccharide of the general formula: (Man) 3-5 -(GleNAc) 2  where Man - a residue of mannose; GlcNAc - a residue of N-acetylglucoseamine. Serum glycoprotein shows the biological activity at superlow doses - at concentrations 10 -14 -10 -19  M, its molecular mass is 12.5 kDa. EFFECT: glycoprotein indicated above, high biological activity of glycoprotein. 6 tbl, 9 ex
The invention belongs to the field of biochemical and biomedicines and relates to an O.jingdongensis sp. antibacterial peptide and a preparation method and use thereof. The O.jingdongensis sp. antibacterial peptide is a single-chain polypeptide consisting of 24 amino acids, the theoretical monoisotopic molecular weight [M+H]+(monoisotopic mass) is 2600.5183Da, and the full-sequence structure of the O.jingdongensis sp. antibacterial peptide is NH2-FLPAVLRVAAKVVPTVFCLISKKC-COOH, wherein the two cysteines at a position-18 and a position-24, namely 18Cys and 24Cys, are in an oxidized disulfide bond (-S-S-) form. The O.jingdongensis sp. antibacterial peptide disclosed by the invention can be used for manufacturing antibacterial medicines or antibacterial agents.
Haematoma is an early complication of tissue expander placement and can lead to infection, capsule contracture and various complications, hindering successful reconstruction. However, no scientific models can accurately predict the risk of haematoma following tissue expansion. Therefore, this study aimed to develop and validate a prediction model for haematoma following tissue expander placement. The medical records of patients who underwent expander placement between 2001 and 2021 were obtained from the clinical database of the Department of Plastic Surgery at the Xijing Hospital. A total of 4579 consecutive patients with 7080 expanders and 179 expanded pocket haematomas were analysed. Multivariate logistic regression analysis identified adult age (P = 0.006), male sex (P < 0.001), scar reconstruction (P = 0.019), perioperative hypertension (P < 0.001), face and neck location (P = 0.002) and activated partial thromboplastin time above the normal range (P < 0.001) as risk factors for haematoma. Therefore, these were included in the prediction model, and a nomogram was constructed. The discrimination of the nomogram was robust (area under the curve: 0.78; 95% confidence interval: 0.72-0.83). Further, the prediction model had a strong fit (Hosmer-Lemeshow test, P = 0.066) and maintained similar discrimination after considering performance optimism (bootstrapped area under the curve: 0.79; 95% confidence interval: 0.73-0.84). This clinical prediction model was created using a generalisable dataset and can be utilised to obtain valid haematoma predictions after expander placement, assisting surgeons in implementing preventive measures or interventions to reduce the occurrence of haematoma.
Objective: The aim of this split-mouth, randomized clinical study is to evaluate the effect of LED or Diode laser-activated bleaching applications on colour change, tooth sensitivity, gingival irritation and temperature variation with 35% hydrogen peroxide bleaching gel after 9 months. Material and Methods: Thirty-five patients with anterior teeth without caries and no restoration will be included in this study. In a split-mouth design, a bleaching agent containing 35% HP (Whiteness HP, FGM) will be used, one side of each jaw will be activated by a diode laser (Epic X, Biolase) and the other side will be activated by an LED (Radii Plus, SDI) light source. During the bleaching treatments, the temperature variations will be recorded using a thermocouple (DT-3891G K type Thermometer datalogger, CEM Instruments) from the buccal surface of canine teeth. Tooth sensitivity will be assessed by Visual Analogue Scale (VAS) before the treatment and during, immediately, 48 hours, 1 week, 1, 6 and 9 months after. Color change will be evaluated by subjective (Vita Classic and Vita 3D Master Bleachguide) and objective methods (Vita Easy Shade, spectrophotometer) before the treatment and immediately, 48 hours, 1 week, 1, 6 and 9 months after. Color change (ΔE and ΔSGU) will be performed by analysis of variance in repeated measurements. Multiple comparisons will be evaluated by Bonferroni test. Temperature variation will be evaluated by t-test in dependent groups. Tooth sensitivity will be analyzed using Friedman test. Wilcoxon test will be used to compare two light sources (Diode Laser/ LED) in each time period (p\< 0.05).
The invention relates to bronchodilatation medicamentous form based on 3,7-dimethyl-purin-2,6-dion in the form of an adjunctive compound and 1,2-ethanediamine (2:1) which with the name of aminophilin is applied in the medical practice as broncholithic agent and diueretic. It has simplified composition, the supplementary substances ensuring the necessary therapeutical plasma concentrations within 12 h by active substance release in stages without having the necessity of multiple administration of the medicament. The medicament can be either in the form of coated tablets containing 100 mg of aminophilin or tablets of extended release containing 350 mg of aminophilin in wt. ratios to the supplementary substances of 2.4:1 and 2.7:1, respectivelyl. The coated tablets contains, in mg: anhydrous aminophilin from 50 to 150, mannitol SD 200 from 10 to 40, colloid silicon dioxide from 0.5 to 4, copolyvidon VA-64 from 2 to 10, talcum powder from 2 to 8, magnesium stearate from 1 to 4 and ehtylcellulose No. 10 from 1.0 to 5.0 as a coating forming substance. The medicamentous form with extended time of release contains, in mg: anhydrous aminophilin from 200 to 400, hydroxypropylmethyl cellulose K100 M from 25 to 60 mannitol SD 200 from 10 to 40, microcrystal cellulose from 10 to 50, colloidal silicon dioxide from 1 to 6, copolyvidon VA-64 from 5 to 20, talcum powder from 5 to 15 and magnesium stearate from 2 to 6. 2 claims
PROBLEM TO BE SOLVED: To obtain a skin cosmetic causing no skin irritancy and having excellent rough skin preventive effect by including vegetation water afforded from olive fruits. SOLUTION: This skin cosmetic contains pref. normally 0.001-10 wt.%, esp. pref. 0.01-5 wt.%, on.a dry basis, of vegetation water afforded from olive fruits. For the vegetation water, an aqueous solution fraction produced in the process of obtaining ordinary olive oil can be used directly, however, it is preferable that it is used in a refined state after removing lipid components, fibrous components, seed crusts and the like as contaminants through filtration or centrifugal separation. This skin cosmetic may be formulated, as necessary, with various ingredients generally used in cosmetic compositions, and can be prepared into any formulation such as ointment, lotion, milky lotion, cream, pack, cataplasm, granules or base makeup.
The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS) - a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF¿165? which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.
Disclosed are complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. Also disclosed are pharmaceutical compositions and uses of the complexes in the manufacture of a medicament for treatment of an individual.
MEKTOVI in combination with encorafenib was evaluated in an open-label, multicenter, single-arm study in patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC) (PHAROS; NCT03915951). Eligible patients had a diagnosis of histologically-confirmed metastatic NSCLC with BRAF V600E mutation that was treatment-naïve or had been previously treated with 1 prior line of systemic therapy in the metastatic setting (platinum-based chemotherapy and/or anti-PD-1/PD-L1 therapies), age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Prior use of BRAF inhibitors or MEK inhibitors was not allowed. 

Patients received MEKTOVI 45 mg orally twice daily and encorafenib 450 mg once daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were objective response rate (ORR) per RECIST v1.1 and duration of response (DoR) as assessed by independent review committee (IRC).

In the efficacy population, BRAF V600E mutation status was determined by prospective local testing using tumor tissue (78%) or blood (22%) specimens. Of the 98 patients with BRAF V600E mutation, 6 patients were enrolled into the trial based on testing of their tumor tissue specimens with the FoundationOne CDx tissue test. Of the remaining 92 patients enrolled based on local testing, 68 patients had their tumor tissue specimens retrospectively confirmed as having BRAF V600E positive status by the FoundationOne CDx tissue test. The remaining patients had either BRAF V600E negative status (n=5) or had unevaluable results (n=19) by the FoundationOne CDx tissue test. In addition, plasma samples from 81 out of 98 patients were retrospectively tested using the FoundationOne Liquid CDx assay. Of the 81 patients, 48 were confirmed positive for BRAF V600E, while 33 patients were BRAF V600E mutation negative by FoundationOne Liquid CDx assay. The remaining 17 samples had unevaluable results with FoundationOne Liquid CDx assay.

The efficacy population included 59 treatment-naïve patients and 39 previously-treated patients. Among these 98 patients, the median age was 70 years (range: 47 to 86); 53% female; 88% White, 7% Asian, 3% Black or African American, and 1% American Indian or Alaska Native; 99% were not Hispanic or Latino; 13% were current smokers and 57% were former smokers; 73% had ECOG PS of 1; and 97% had adenocarcinoma. All patients had metastatic disease and 8% had brain metastases at baseline.

Efficacy results for patients with BRAF V600E mutation-positive metastatic NSCLC are summarized in Table 8.
Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
An automated urine-output-measurement system can include single-patient equipment and/or multi-patient equipment. The single-patient equipment can include a urinary catheter and a urine-collection system. The urine-collection system can include drainage tubing and a drainage receptacle. The multi-patient equipment can include a urine monitor. The urine monitor can include a housing having a cavity configured to completely encompass the drainage receptacle, a urine measurement device configured to measure urine output into the drainage receptacle, and an integrated display screen configured to display patient information including measurements of the urine output. A method of the automated urine-output-measurement system can include placing the drainage receptacle in the urine monitor of the automated urine-output-measurement system, and confirming a volume of urine in the drainage receptacle with that indicated on the urine monitor once a patient has produced urine.
The effect of chlorhexidine gluconate oral rinse, 0.12% on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. (See CONTRAINDICATIONS).
PURPOSE:To obtain an emulsion-type cosmetic having high moisture-retaining effect only by the addition of a small amount of a betaine having excellent moisture-retaining action and touch-improving action, giving extremely good touch after use by including the betaine as an active ingredient. CONSTITUTION:This emulsion type cosmetic contains a betaine expressed by the formula (another name: trimethylglycine, glycine betaine or alkyldimethyl be taine) as an active ingredient. The betaine expressed by the formula is included in an amount of 0.05-20 pts. wt., preferably 2-5 pts. wt. This emulsion type cosmetic can contain, e.g. a hydrocarbon such as squalane, oils and fats such as oilve oil, wax such as lanlin, a fatty acid such as stearic acid, a higher alcohol such as cetanol, synthetic ester such as glycerol triester, other oil component, a thickening agent such as quince seed, an alcohol such as ethanol, a surfactant such as glycerol monostearate, an alkali such as triethanolamine, a chelating agent, a preservative, an antioxidant, a perfume, a pigment, a humectant, a buffer and other chemicals, etc., in addition to the essential ingredient.
The precise means by which this inhibition relieves angina has not been fully determined, but includes at least the following two mechanisms:

1) Relaxation And Prevention Of Coronary Artery Spasm: Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm, and is responsible for the effectiveness of nifedipine in vasospastic (Prinzmetal’s or variant) angina. Whether this effect plays any role in classical angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.

2) Reduction Of Oxygen Utilization: Nifedipine regularly reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing the total peripheral resistance (afterload) against which the heart works. This unloading of the heart reduces myocardial energy consumption and oxygen requirements and probably accounts for the effectiveness of nifedipine in chronic stable angina.
Multicenter prospective study on patients aged between 12 and 50 years, requiring orthodontic treatment with premolar extractions and closure of the extraction spaces by distalization of the 6 anterior teeth. In the experimental group (50 patients) distalization will be performed using skeletal anchorage (MINISCREW). In the control group (50 patients), distalization will be by dental anchorage.

The main evaluation criterion will be extraction space closure after 8 months of treatment. Angle class I cuspid and the parallelism of the dental axes will also be taken into account. Evaluations will be made by very precise radiological analysis using 3D CT-scan. Examinations will be done before and after closure of the extraction sites and will assess treatment efficacy using skeletal anchorage versus dental anchorage. Patients will also be requested to complete a satisfaction questionnaire. The study will comprise an inclusion appointment during which patient consent will be obtained and a regular monthly appointment during the 8 months of active treatment and space closure.
The invention comprises bases of the formula <FORM:0980003/C2/1> and quaternary derivatives thereof of the formula <FORM:0980003/C2/2> wherein R represents a C9- 17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1- 4 alkyl group or a C1- 4 hydroxyalky group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine, or pyrrolidine group; R3 represents a C1- 4 alkyl group, a C1- 4 hydroxy-alkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate. The bases are prepared by reacting together substantially equimolecular proportions of an alkali metal salt of a carboxylic acid of the formula R.COOH with an epihalohydrin and a secondary amine of the formula HNR1R2 in a solvent medium, and separating of the alkali metal halide formed simultaneously.  The quaternary compounds are prepared by quaternating the corresponding base with a compound R3X.ALSO:A liquid shampoo composition contains 0.5 to 10% by weight of a quaternary compound of the formula <FORM:0980003/C4-C5/1> wherein R represents a C9- 17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1- 4 alkyl or C1- 4 hydroxyalkyl group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine or pyrrolidine group; R3 represents a C1- 4 alkyl group, a C1- 4 hydroxyalkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate. Optional ingredients specified are lauryl alcohol ethylene oxide condensate, lauryl imidazoline quaternized with monochloracetic acid, water and lactic acid.ALSO:An anti-scurf lotion comprises an aqueous ethanol solution of a quaternary compound of the formula <FORM:0980003/A5-A6/1> wherein R represents a C9-17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1-4 alkyl or C1-4 hydroxyalkyl group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine or pyrrolidine group; R3 represents a C1-4 alkyl group, a C1-4 hydroxyalkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate.
We propose a novel frailty model with change points applying random effects to a Cox proportional hazard model to adjust the heterogeneity between clusters. In the specially focused eight Empowered Action Group (EAG) states in India, there are problems with different survival curves for children up to the age of five in different states. Therefore, when analyzing the survival times for the eight EAG states, we need to adjust for the effects among states (clusters). Because the frailty model includes random effects, the parameters are estimated using the expectation-maximization (EM) algorithm. Additionally, our model needs to estimate change points; we thus propose a new algorithm extending the conventional estimation algorithm to the frailty model with change points to solve the problem. We show a practical example to demonstrate how to estimate the change point and the parameters of the distribution of random effect. Our proposed model can be easily analyzed using the existing R package. We conducted simulation studies with three scenarios to confirm the performance of our proposed model. We re-analyzed the survival time data of the eight EAG states in India to show the difference in analysis results with and without random effect. In conclusion, we confirmed that the frailty model with change points has a higher accuracy than the model without a random effect. Our proposed model is useful when heterogeneity needs to be taken into account. Additionally, the absence of heterogeneity did not affect the estimation of the regression parameters.
Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours. Docetaxel 75mg/m2 every 21 days a cycle.
PURPOSE: An external use skin composition containing ginseng berry extract is provided to relieve skin pain with safety to the human body. CONSTITUTION: An external use skin composition for relieving skin pain contains 0.0001-50 weight% of ginseng berry extract as an active ingredient. The ginseng berry extract is prepared by removing seeds from ginseng berries, drying ginseng berry pulps and peels by the sunlight or hot wind; and isolating using water or ethanol. The composition is a pharmaceutical or cosmetic composition. The pharmaceutical composition additionally contains antiseptic, stabilizing agent, or emulsifier and is manufactured in the form of lotion, ointment, gel, cream, or patch. The cosmetic composition is used in the form of essence, pack, gel, essence, eye cream, eye essence, cleansing cream, and body essence.
Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.